4.3. Prospects for Further Development
VIRUS
Some serum samples collected during phase II were tested against strains of later circulating SARS-CoV-2 variants: Delta and Omicron (BA.2). Overall, 57.1% and 61.9% of samples neutralized Delta and Omicron strains [CoviVac production platform uses an infectious virus primarily isolated from the natural viral population multiplied in Vero cells expressing ACE2 receptor [